Page 749 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 52 Rheumatoid Arthritis 721

22. de Hair MJ, van de Sande MG, Ramwadhdoebe TH, et al. Features of the 38. Walter GJ, Fleskens V, Frederiksen KS, et al. Phenotypic, functional, and
synovium of individuals at risk of developing rheumatoid arthritis: gene expression profiling of peripheral CD45RA+ and CD45RO+
implications for understanding preclinical rheumatoid arthritis. Arthritis CD4+CD25+CD127(low) Treg cells in patients with chronic rheumatoid
Rheumatol 2014;66:513. arthritis. Arthritis Rheumatol 2016;68:103.
23. van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, et al. 39. Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: the link
Rheumatoid arthritis is a heterogeneous disease: evidence for differences between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol
in the activation of the STAT-1 pathway between rheumatoid tissues. 2005;1:47.
Arthritis Rheum 2003;48:2132. 40. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and
24. Vicente R, Noël D, Pers YM, et al. Deregulation and therapeutic potential bone loss by human autoantibodies against citrullinated vimentin. J Clin
of microRNAs in arthritic diseases. Nat Rev Rheumatol 2016;12:211. Invest 2012;122:1791–802.
25. Sacre SM, Drexler SK, Andreakos E, et al. Could toll-like receptors 41. Hayashi M, Nakashima T, Taniguchi M, et al. Osteoprotection by
provide a missing link in chronic inflammation in rheumatoid arthritis? semaphorin 3A. Nature 2012;485:69.
Lessons from a study on human rheumatoid tissue. Ann Rheum Dis 42. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism
2007;66:81. Association 1987 revised criteria for the classification of rheumatoid
26. Pettit AR, Thomas R. Dendritic cells: the driving force behind arthritis. Arthritis Rheum 1988;31:315.
autoimmunity in rheumatoid arthritis? Immunol Cell Biol 1999;77:420. 43. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis
27. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in classification criteria: an American College of Rheumatology/European
rheumatoid arthritis. Semin Immunol 2003;15:15. League Against Rheumatism collaborative initiative. Arthritis Rheum
28. Kollias G, Papadaki P, Apparailly F, et al. Animal models for arthritis: 2010;62:2569.
innovative tools for prevention and treatment. Ann Rheum Dis 44. Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients
2011;70:1357. with arthralgia is strongly associated with anti-citrullinated protein
29. James EA, Rieck M, Pieper J, et al. Citrulline-specific Th1 cells are antibody status: a prospective cohort study. Ann Rheum Dis 2010;69:
increased in rheumatoid arthritis and their frequency is influenced by 490.
disease duration and therapy. Arthritis Rheumatol 2014;66:1712. 45. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight
30. van Venrooij WJ, Vossenaar ER, Zendman AJ. Anti-CCP antibodies: the control for rheumatoid arthritis (the TICORA study): a single-blind
new rheumatoid factor in the serology of rheumatoid arthritis. randomised controlled trial. Lancet 2004;364:263.
Autoimmun Rev 2004;3(Suppl. 1):S17. 46. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical
31. Klareskog L, Rönnelid J, Lundberg K, et al. Immunity to citrullinated and radiographic outcomes of four different treatment strategies in
proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26:651. patients with early rheumatoid arthritis (the BeSt study): a randomized,
32. Klarenbeek PL, de Hair MJ, Doorenspleet ME, et al. Inflamed target tissue controlled trial. Arthritis Rheum 2005;52:3381.
provides a specific niche for highly expanded T-cell clones in early 47. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis:
human autoimmune disease. Ann Rheum Dis 2012;71:1088. what have we learned? Annu Rev Immunol 2001;19:163.
33. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell 48. Kishimoto T. Interleukin-6: from basic science to medicine—40 years in
apoptosis in the rheumatoid synovium. J Clin Invest 1997;99:439. immunology. Annu Rev Immunol 2005;23:1.
34. Cope A, Le Friec G, Cardone J, et al. The Th1 life cycle: molecular control 49. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell
of IFN-γ to IL-10 switching. Trends Immunol 2011;32:278. signaling. Immunol Rev 2009;228:273.
35. Evans HG, Roostalu U, Walter GJ, et al. TNF-α blockade induces IL-10 50. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid
expression in human CD4+ T cells. Nat Commun 2014;5:3199. arthritis by selective inhibition of T-cell activation with fusion protein
36. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid CTLA4Ig. N Engl J Med 2003;349:1907.
arthritis. Nat Rev Immunol 2007;7:429. 51. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and
37. Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3(+) regulatory other autoimmune diseases. Nat Rev Immunol 2006;6:394.
T cells in systemic autoimmune diseases. Autoimmun Rev
2011;10(12):744–55.